Drugs Made In America Acquisition II Corp. (DMII) Total Liabilities (2024 - 2026)

Drugs Made In America Acquisition (DMII) has reported Total Liabilities for 3 consecutive years, with $18.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities changed N/A year-over-year to $18.1 million in Q2 2026; TTM through Jun 2026 was $18.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $17.8 million, up 6886.68% from the prior year.
• Total Liabilities was $18.1 million for Q2 2026 at Drugs Made In America Acquisition, up from $17.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $18.2 million in Q3 2025 and troughed at $254783.0 in Q4 2024.
• A 3-year average of $13.6 million and a median of $18.0 million in 2025 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 6886.68% in 2025, down 6886.68% in 2025.
• Over 3 years, Total Liabilities stood at $254783.0 in 2024, then jumped by 6886.68% to $17.8 million in 2025, then rose by 1.93% to $18.1 million in 2026.
• The last three Total Liabilities figures came in at $18.1 million (Q2 2026), $17.8 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.